Role of Omega-DEK in Childhood Apraxia of Speech

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Childhood Apraxia of Speech, Verbal Apraxia, Autism

In brief

This is a 20-week study for children between 3 and 6 years old with confirmed childhood apraxia of speech (CAS). The study includes a 12-week open-label pilot feasibility study of an investigational drug (Omega-DEK) plus L-carnitine (Carnitor®), which is followed by an 8-week randomized, placebo-controlled discontinuation period among the same study participants.

Key facts

Study ID

NCT07216001

Run by

Claudia R. Morris

People needed

34

Starts

2026-11-01

Expected to finish

2027-12-01

Last updated by the study team

2026-07-29

Who can join

Age: 3 and older, up to 6. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's Healthcare of Atlanta — Atlanta, Georgia, United States
• Marcus Autism Center — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.